CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes

Launched by VIDA RECOLETAS SEVILLA · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a protein called CENP-V in human egg cells (oocytes) to see if it can help identify damage caused by aging or the freezing and thawing process of these eggs. As women get older, their fertility can decline, and this study aims to understand how the levels of CENP-V change in eggs from older women compared to younger women. By measuring this protein, researchers hope to create a new way to predict which eggs might have a lower chance of survival after being thawed, which is important for women undergoing fertility treatments.

To participate in this trial, women aged 18 to 45 who are either experiencing infertility due to advanced maternal age (36-45 years) or who have undergone egg freezing and thawing procedures can be eligible. The study will analyze immature eggs that are not intended for use in treatment, ensuring that only those that would be discarded are examined. Participants can expect to contribute to valuable research that could improve fertility treatments and outcomes for many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Group of patients with advanced maternal age (AMA): patients aged 36-45 years with AMA etiology as the main factor of infertility undergoing controlled ovarian stimulation.
• * Group of patients with vitrification / thawing of their oocytes: patients between 18-45 years of age who underwent oocyte vitrification to later, in the study cycle, thaw their oocytes. In this group we contemplate two subgroups:
• • Patients with vitrified / thawed oocytes and AMA: between 36-45 years at the moment of oocytes vitrification.
• • Patients with vitrified / thawed oocytes and non-AMA: between 18-35 years at the moment of oocytes vitrification.
• • Group of control patients: patients and donors with normal etiology, aged 18-35 years, undergoing controlled ovarian stimulation and collection procedures.
• Exclusion Criteria:
• • Patients with pathologies affecting the oocyte quality (PCO, POI, endometriosis, oncology patients, etc.).
• • Patients/donors with oocyte cryopreserved by slow freezing technique.